{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:09:09Z","timestamp":1759972149678,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009438","name":"National Center of Neurology and Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.braindev.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T07:41:57Z","timestamp":1579938117000},"page":"348-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expectations and anxieties of Duchenne muscular dystrophy patients and their families during the first-in-human clinical trial of NS-065\/NCNP-01"],"prefix":"10.1016","volume":"42","author":[{"given":"Reiko","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisateru","family":"Tachimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"En","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Tamaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin'ichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2020.01.001_b0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2020.01.001_b0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2020.01.001_b0015","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2147\/NDT.S93873","article-title":"Current and emerging treatment strategies for Duchenne muscular dystrophy","volume":"12","author":"Mah","year":"2016","journal-title":"Neuropsychiatri Dis Treat"},{"key":"10.1016\/j.braindev.2020.01.001_b0020","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00439-016-1725-z","article-title":"Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy","volume":"135","author":"Robinson-Hamm","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.braindev.2020.01.001_b0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutation","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.braindev.2020.01.001_b0030","unstructured":"U.S. Food and Drug Administration (FDA), Drug Approval Package: Exondys 51 Injection (eteplirsen) (FDA, 2016); www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_TOC.cfm."},{"key":"10.1016\/j.braindev.2020.01.001_b0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","author":"Komaki","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.braindev.2020.01.001_b0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/jhg.2010.49","article-title":"Mutation spectrum of the dystrophin gene in 442 Duchenne\/Becker muscular dystrophy cases from one Japanese referral center","volume":"55","author":"Takeshima","year":"2010","journal-title":"J Hum Genet"},{"key":"10.1016\/j.braindev.2020.01.001_b0045","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/0883073815570154","article-title":"Cognitive and neurobehavioral profile in boys with Duchenne Muscular Dystrophy","volume":"30","author":"Banihani","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2020.01.001_b0050","unstructured":"ICH Harmonaized Tripartite Guideline. Clinical Investigation of Medicinal Products in the paediatric population. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E11\/Step4\/E11_Guideline.pdf; 2000 [accessed 28.12.16]."},{"key":"10.1016\/j.braindev.2020.01.001_b0055","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/1097-0142(20010515)91:10<1949::AID-CNCR1218>3.0.CO;2-A","article-title":"The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial","volume":"91","author":"Cohen","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.braindev.2020.01.001_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6939-14-7","article-title":"Effect of child health status on parents\u2019 allowing children to participate in paediatric research","volume":"14","author":"Vanhelst","year":"2013","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.braindev.2020.01.001_b0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2214.2012.01387.x","article-title":"Emotional impact of genetic trials in progressive paediatric disorders: a dose-ranging exon-skipping trial in Duchenne muscular dystrophy","volume":"39","author":"Garralda","year":"2013","journal-title":"Child Care Health Dev"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S038776042030019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S038776042030019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:48:48Z","timestamp":1759952928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S038776042030019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S038776042030019X"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2020.01.001","relation":{},"ISSN":["0387-7604"],"issn-type":[{"type":"print","value":"0387-7604"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expectations and anxieties of Duchenne muscular dystrophy patients and their families during the first-in-human clinical trial of NS-065\/NCNP-01","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology.","name":"copyright","label":"Copyright"}]}}